Genmab — Marts 2016
-
Sorry, jeg læste 6 - 7 milliarder, men du mente naturligvis 6 - 7 måneder
-
De betaler vist godt
-
Methodology: Our 12-month price target of DKK950 is based on a weighted average of our
DCF valuation of DKr715/share (70% weighting) and an M&A component of DKK1,500/share
(30% weighting).
Risks to our view and price target: Upside: Stronger-than-expect Darzalex launch.
Downside: Sales launch slower than expected, clinical trials of Darzalex in earlier stage
therapy negative, competition from immuno-oncology agents. -
Slå nu koldt vand i blodet....uanset hvad kursen er, er det vel sælger der skal acceptere prisen...
-
Jeg er overbeviste om brugerne i dette forum er helt rolige, men det klinger bare hult, når GS sænker kursmål på baggrund af fackts som burde forstærke casen. De burde fremstå professionelle og i stedet ligner de amatøragtige nybegyndere med en anden dagsorden, som er gennemsyret af spekulative bagtanker.
-
Ja...de burde anmeldes for kursmanipulation

-
hvis de skulle bakke op om short så skal de jo have et salg target et stykke under den aktuelle kurs
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind